Our Portfolio

LEXEO Therapeutics, Inc.

Ronald Crystal, MD | New York, United States

Project Overview

  • Biotechnology/For Profit Organization Type
  • $1,997,865 Funding Amount
  • 5/27/20 — 5/27/21 Project Duration
  • Clinical Program
  • zzAPOE Target
  • Clinical Phase 1 Therapeutic Stage
  • Active Status

LEXEO Therapeutics, Inc.

Ronald Crystal, MD | New York, United States

Phase I Clinical Trial for the AAV mediated treatment of APOE4 homozygous Alzheimer’s Disease

The primary objective of the Phase I study for LXc-001 is to determine the safety/toxicity and establish a maximum tolerable dose of intracisternal delivery of AAV gene therapy to APOE4 homozygotes with AD. 

GET IN TOUCH